SIRT1与肝细胞癌病理及预后的研究进展及靶向治疗展望  

Research Progress in the Pathology and Prognosis of SIRT1 and Hepatocellular Carcinoma and Prospects for Targeted Therapy

作　　者：林治华 王俊伟[1,2] 邓雅庭 李静 王娟 LIN Zhihua;WANG Junwei;DENG Yating;LI Jing;WANG Juan(College of Pharmacy & Bioengineering,Chongqing University of Technology,Chongqing 400054,China;Laboratory of Screening and Activity Evaluation of Targeted Drugs,Chongqing 400054,China;School of Chemistry and Chemical Engineering,Chongqing University,Chongqing 400044,China)

机构地区：[1]重庆理工大学药学与生物工程学院,重庆400054 [2]靶向药物筛选与活性评价重庆市高校重点实验室,重庆400054 [3]重庆大学化学化工学院,重庆400044

出　　处：《重庆理工大学学报（自然科学）》2019年第7期221-227,共7页Journal of Chongqing University of Technology：Natural Science

基　　金：国家自然科学基金资助项目(81171508);重庆自然科学基金重点资助项目(cstc2015jcyjBX0080);重庆市教委科学技术研究项目(KJZD-K201801102,KJQN201801132);重庆理工大学科研启动基金资助项目(2017ZD42)

摘　　要：沉默信息调节因子2同系物1(SIRT1)是一种多层面的烟酰胺腺嘌呤二核苷酸(NAD+)依赖性蛋白脱乙酰酶,参与多种细胞过程,在细胞生存、衰老、凋亡和代谢以及癌变等生物学过程中扮演着重要角色。同时,有研究证实SIRT1分子与多种肿瘤的发生发展以及临床预后密切相关,临床研究发现,在肝细胞癌中SIRT1的表达量呈上升的趋势,特别是在肝细胞癌的演变中发挥了重要的作用。SIRT1有望成为肝细胞癌的治疗靶点。对SIRT1在肝细胞癌中的作用进行了综述,为进一步基于SIRT1开展肝癌治疗药物提供参考。Silencing regulator 2 homolog 1 (SIRT1) is a multi-faceted,nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylase.It is involved in a variety of cellular processes and plays an important role in biological processes such as cell survival,senescence,apoptosis and metabolism,and cancer.At the same time,studies have confirmed that SIRT1 molecules are closely related to the occurrence and development of various tumors and clinical prognosis.Clinical studies have found that the expression of SIRT1 in hepatocellular carcinoma is increasing,especially in the evolution of hepatocellular carcinoma.SIRT1 is expected to be a therapeutic target for hepatocellular carcinoma.This article reviews the role of SIRT1 in hepatocellular carcinoma and provides a reference for further development of liver cancer treatment based on SIRT1.

关 键 词：SIRT1 肝细胞癌 分子机制 靶点 

分 类 号：R739.9[医药卫生—肿瘤]